Skip to content
2000
Volume 21, Issue 17
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Reverse transcription of human immunodeficiency virus type 1 (HIV-1) is a crucial step in the life cycle initiated by the viral-coded reverse transcriptase (RT), functioning as RNA- and DNA-dependent DNA polymerase (RDDP and DDDP) and the ribonuclease H (RNase H). The RNase H functions to degrade the RNA strand of the RNA:DNA heteroduplex, which makes it an attractive target for rational anti-HIV-1 drug design and development. Although development of drugs targeting the DNA polymerase have been highly successful, the discovery of drugable inhibitors of HIV RNase H is still in its infancy and none of RNase H inhibitors has reached the clinical development stage currently. This review describes the recent progress in the HIV-1 RNase H inhibitors, focusing on their chemical feature, mechanism and the structure-activity relationship (SAR).

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867321666140120121158
2014-06-01
2025-05-10
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867321666140120121158
Loading

  • Article Type:
    Research Article
Keyword(s): AIDS; drug design; HIV-1; RNase H inhibitors; RT; SAR
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test